Pharmacoprophylaxis and co-medications in allergen-specific immunotherapy;Pharmakoprophylaxe und Begleitmedikation bei spezifischer Immuntherapie

Hautarzt

Volumn 62, Issue 9, 2011, Pages 663-670

  Wedi, B ^a   Rueff F ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antihistamines; Co medication; Hyposensitization; Pharmacoprophylaxis; Specific immunotherapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOMODULATING AGENT; INSECT VENOM; OMALIZUMAB;

ALLERGY; ARTICLE; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; OFF LABEL DRUG USE; UNSPECIFIED SIDE EFFECT;

ANAPHYLAXIS; ANTI-ALLERGIC AGENTS; COMBINED MODALITY THERAPY; DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; EPITOPES; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; RHINITIS, ALLERGIC, PERENNIAL;

EID: 80052649695     PISSN: 00178470     EISSN: 14321173     Source Type: Journal    
DOI: 10.1007/s00105-011-2157-2     Document Type: Article

References (43)

1. Averbeck M, Gebhardt C, Renner R et al (2008) Omalizumab helps to induce tolerability in a patient with wasp venom allergy and repeated adverse reactions during specific immunotherapy. Allergy 63:509
2. Berchtold E, Maibach R, Müller U (1992) Reduction of side effects from rush-immunotherapy with honeybee venom by pretreatment with terfenadine. Clin Exp Allergy 22:59-65
3. Brockow K, Kiehn M, Riethmuller C et al (1997) Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 100:458-463
4. Calderon MA, Alves B, Jacobson M et al (2007) Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev CD001936
5. Casale TB, Busse WW, Kline JN et al (2006) Omal-izumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117:134-140 (Pubitemid 43017150)
6. Cox L, Platts-Mills TA, Finegold I et al (2007) American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 120:1373-1377 (Pubitemid 350216610)
7. Eiwegger T, Gruber S, Geiger C et al (2009) Impact of systemic immuno-suppression after solid organ transplantation on allergen-specific responses. Allergy 66:271-278
8. Galera C, Soohun N, Zankar N et al (2009) Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 19:225-229
9. Golden DB, Moffitt J, Nicklas RA et al (2011) Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 127:852-854
10. Hejjaoui A, Ferrando R, Dhivert H et al (1992) Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol 89:925-933
11. Johansen P, Senti G, Martinez Gomez JM, Kündig TM (2007) Medication with antihistamines impairs allergen-specific immunotherapy in mice. Clin Exp Allergy 38:512-519 (Pubitemid 351208076)
12. Kleine-Tebbe J, Bufe A, Ebner C et al (2009) Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J 18:508-537
13. Klunker S, Saggar LR, Seyfert-Margolis V et al (2007) Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 120:688-695 (Pubitemid 47320761)
14. Koberlein J, Kothe AC, Schaffert C (2011) Determinants of patient compliance in allergic rhino-conjunctivitis. Curr Opin Allergy Clin Immunol 11:192-199
15. Kontou-Fili K (2008) High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 63:376-378 (Pubitemid 351224685)
16. Kopp MV, Brauburger J, Riedinger F et al (2002) The effect of anti-IgE treatment on in vitro leuko-triene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 110:728-735 (Pubitemid 35423175)
17. Kopp MV, Stenglein S, Kamin W et al (2007) Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol 18:523-527 (Pubitemid 47206746)
18. Koschel D, Hoeffken G (2008) Hymenoptera venom immunotherapy and autoimmune diseases. Allergy 63(Suppl 88):81
19. Kuehr J, Brauburger J, Zielen S et al (2002) Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109:274-280 (Pubitemid 34158294)
20. Lang DM, Alpern MB, Visintainer PF, Smith ST (1993) Elevated risk of anaphylactoid reaction from radiographic contrast media is associated with both beta-blocker exposure and cardiovascular disorders. Arch Intern Med 153:2033-2040 (Pubitemid 23263566)
21. Massanari M, Nelson H, Casale T et al (2010) Effect of pretreatment with omalizumab on thetolerabi-lity of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 125:383-389
22. Müller UR, Haeberli G (2005) Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 115:606-610 (Pubitemid 40341717)
23. Müller U, Hari Y, Berchtold E (2001) Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 107:81-86 (Pubitemid 32105249)
24. Müller URJutel M, Reimers A et al (2008) Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J Allergy Clin Immunol 122:1001-1007
25. Nielsen L, Johnsen CR, Mosbech H et al (1996) Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 97:1207-1213
26. Ohashi Y, Nakai Y, Murata K (2006) Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Ann Allergy Asthma Immunol 96:600-605
27. Portnoy J, Bagstad K, Kanarek H et al (1994) Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Allergy 73:409-418 (Pubitemid 24368195)
28. Przybilla B, Ruëff F, Walker A et al (2011) Diagnose und Therapie der Bienen-und Wespengiftallergie. Allergo J (im Druck)
29. Reimers A, Hari Y, Müller U (2000) Reduction of side-effects from ultra rush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind placebo-controlled trial. Allergy 55:484-488 (Pubitemid 30230359)
30. Rerinck HC, Rueff F, Przybilla B (2008) Recurrent severe anaphylactic reactions to venom immunotherapy (VIT): omalizumab induces tolerance. J Allergy Clin Immunol 121:129
31. Rolinck-Werninghaus C, Hamelmann E, Keil T et al (2004) The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 59:973-979 (Pubitemid 39141410)
32. Ruëff F, Przybilla B, Biló M-B et al (2009) Predictors of severe systemic anaphylactic reactions in Hymenoptera venom allergy: the importance of baseline serum tryptase concentration and concurrent clinical variables. J Allergy Clin Immunol 124:1047-1054
33. Ruëff F, Räwer H-C, Eben R, Przybilla B (2009) Management von Nebenwirkungen bei subkutaner Hyposensibilisierung. Allergo J 18:618-624
34. Ruëff F, Przybilla B, Biló M-B et al (2010) Predictors of side effects during the build-up phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 126:105-111
35. Schulze J, Rose M, Zielen S (2007) Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 62:963-964 (Pubitemid 47037850)
36. Soriano GV, Gonzalez DP, Niveiro HE (2008) Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Investig Allergol Clin Immunol 18:225-226
37. Suzuki Y, Ra C (2009) Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: aspirin modulation of IgE-dependent mast cell activation: role of aspirin-induced exacerbation of immediate allergy. J Pharmacol Sci 110:237-244
38. Tunon-Lara JM de, Villanueva P, Marcos M,Tay-tard A (1992) ACE inhibitors and anaphylactoid reactions during venom immunotherapy. Lancet 340:908
39. Wantke MD, Demmer CC, Götz M, Jarisch R (1993) Reduction of side effects of specific immunotherapy. J Allergy Clin Immunol 92:497-498 (Pubitemid 24088704)
40. Wedi B, Wieczorek D, Raap U, Kapp A (2008) Anti-IgE treatment overcomes intolerability of honeybee-venom ultra-rush immunotherapy in indolent systemic mastocytosis. In: Holgate ST, Marone G, Ring J (Hrsg) Cellular and molecular targets in allergy and clinical immunology. Hogrefe, Göttingen, S 182-183
41. White KM, England RW (2008) Safety of angioten-sin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol 101:426-430
42. Wieczorek D, Kapp A, Wedi B (2005) Omalizumab ermöglicht Einleitung einer Hyposensibilisierungs-behandlung mit Bienengift bei Risikopatient mit erhöhter Serumtryptase. Allergo J 14:515
43. Wöhrl S, Gamper S, Hemmer W et al (2007) Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol 144:137-142 (Pubitemid 47414328)